Protara Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- A key executive is leavingSince Jun 29, 2026+3.3
Trials
- TARAProtara Therapeutics3Calm
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
Signing up patientsPhase 3284 patientsMain results: Apr 2028 - TARAProtara Therapeutics3Calm
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Signing up patientsPhase 2131 patientsMain results: Oct 2031
Key executives leaving
From the last 12 months of the company's SEC reports.
Jun 29, 2026
“Protara Therapeutics, Inc. (the “Company”) announced that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities, effective as of June 26, 2026.”
Read the filing ↗
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
1 sale (1 not pre-planned) · 0 purchases
- Shefferman JesseCEO and President · Jun 29, 2026Sold 215,687 sharesabout $882 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.